These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29631036)

  • 1. A Case of Adenocarcinoma of the Lung With EGFR T790 Mutation Presenting With Chylous Ascites.
    Nakashima K; Hara Y; Sato T; Shinkai M; Kaneko T
    J Thorac Oncol; 2018 Aug; 13(8):1227-1228. PubMed ID: 29631036
    [No Abstract]   [Full Text] [Related]  

  • 2. A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.
    Li S; Zhao J; Wang Q
    J Thorac Oncol; 2018 Jun; 13(6):e97-e101. PubMed ID: 29501421
    [No Abstract]   [Full Text] [Related]  

  • 3. Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.
    Zaemes J; Hall RD; Gentzler RD
    J Thorac Oncol; 2018 Aug; 13(8):e136-e137. PubMed ID: 30049373
    [No Abstract]   [Full Text] [Related]  

  • 4. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 5. Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma.
    Chang LC; Chen KY; Shih JY; Yu CJ; Hsieh MS
    J Thorac Oncol; 2017 Jul; 12(7):e94-e95. PubMed ID: 28629547
    [No Abstract]   [Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Mutation Detection in Cerebrospinal Fluid of Lung Adenocarcinoma Patients with Leptomeningeal Metastasis.
    Huang R; Ge M; Zhou X; Ji X; Liao L; Liang X; Zhan Q
    Cancer Biother Radiopharm; 2019 Mar; 34(2):128-133. PubMed ID: 30452286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
    Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
    Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
    [No Abstract]   [Full Text] [Related]  

  • 8. [Lung adenocarcinoma with epidermal growth factor receptor mutation transferred to the oral cavity: a report of two cases].
    Deng HY; Wang X; Chen H; Wu JJ; Wang K; Jia Y; Liu C; Yin DJ; Liu YP
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2019 Oct; 54(10):691-693. PubMed ID: 31607006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
    Fan J; Dai X; Nie X
    J Thorac Oncol; 2018 Mar; 13(3):e45-e48. PubMed ID: 29472061
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.
    Chen HF; Wang WX; Li XL; Xu CW; Du KQ; Zhu YC; Fang MY
    J Thorac Oncol; 2019 Oct; 14(10):e217-e219. PubMed ID: 31558230
    [No Abstract]   [Full Text] [Related]  

  • 11. Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.
    Wang X; Zhou L; Yin JC; Wu X; Shao YW; Gao B
    J Thorac Oncol; 2019 May; 14(5):e85-e88. PubMed ID: 30711650
    [No Abstract]   [Full Text] [Related]  

  • 12. EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
    Ruiz-Patiño A; Castro CD; Ricaurte LM; Cardona AF; Rojas L; Zatarain-Barrón ZL; Wills B; Reguart N; Carranza H; Vargas C; Otero J; Corrales L; Martín C; Archila P; Rodriguez J; Avila J; Bravo M; Pino LE; Rosell R; Arrieta O;
    Target Oncol; 2018 Oct; 13(5):621-629. PubMed ID: 30284706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid metastasis of pulmonary adenocarcinoma with EGFR G719A mutation: Genetic confirmation with liquid-based cytology specimens.
    Yamada Y; Shirahase H; Fukiya M; Yoshizawa A; Minamiguchi S; Ozasa H; Haga H
    Cytopathology; 2021 May; 32(3):364-366. PubMed ID: 33184941
    [No Abstract]   [Full Text] [Related]  

  • 14. Adenocarcinoma in situ in type I congenital pulmonary airway malformation.
    Santosham R; Santosham R; Tirunagari V; Jacob SS
    Asian Cardiovasc Thorac Ann; 2019 Sep; 27(7):606-608. PubMed ID: 31226882
    [No Abstract]   [Full Text] [Related]  

  • 15. Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.
    Baglivo S; Ricciuti B; Ludovini V; Metro G; Siggillino A; De Giglio A; Chiari R
    J Thorac Oncol; 2018 Aug; 13(8):e145-e147. PubMed ID: 30049377
    [No Abstract]   [Full Text] [Related]  

  • 16. Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
    Koike C; Okudela K; Matsumura M; Mitsui H; Suzuki T; Arai H; Kataoka T; Ishikawa Y; Umeda S; Tateishi Y; Ohashi K
    Histol Histopathol; 2021 Mar; 36(3):305-315. PubMed ID: 33368138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of EGFR T790M in a Large Amount of Malignant Ascites Cellblock.
    Ishioka K; Sasada S; Ohgino K; Sakai T; Takahashi S; Xu C; Sugihara K; Nakamura M
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1185-1187. PubMed ID: 30158416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.
    Niogret J; Coudert B; Boidot R
    J Thorac Oncol; 2018 Jul; 13(7):e113. PubMed ID: 29935845
    [No Abstract]   [Full Text] [Related]  

  • 19. A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review.
    Sharma P; Mahadevia H; Donepudi S; Kujtan L; Gustafson B; Ponvilawan B; Al-Obaidi A; Subramanian J; Bansal D
    Clin Lung Cancer; 2024 Jul; 25(5):479-482. PubMed ID: 38777674
    [No Abstract]   [Full Text] [Related]  

  • 20. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
    BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.